Shionogi & Co. Ltd. has synthesized spiroheterocycle derivatives acting as 5-HT2A and 5-HT2C receptor antagonists and/or inverse agonists reported to be useful for the treatment of neurodegeneration.

(A) GPCR agonists increase the proportion of active receptor states; inverse agonists decrease the proportion of active receptor states; and antagonists inhibit the action of other ligands. (B) In ...

Dr. Paul Christo answers the question: 'What Is An Agonist-Antagonist Medicine?' — -- Question: What Is An Agonist-Antagonist Medicine And When Is It Used For Pain Relief? Answer: ...

CRB-913 is a novel highly peripherally restricted CB1 inverse agonist with potent monotherapy efficacy in DIO mouse model Weight loss and related outcomes markedly enhanced in combination with ...

MONTREAL--(BUSINESS WIRE)--Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced that following the receipt of a No Objection Letter (NOL) from ...